2 Pharma Stocks Reacting to Big FDA Announcement

The FDA approved Mylan's cancer infection drug Fulphila

by Patrick Martin

Published on Jun 5, 2018 at 10:14 AM

The Food and Drug Administration (FDA) just approved Fulphila, a cancer infection treatment developed by Mylan N.V. (NASDAQ:MYL) and India-based Biocon (BION). The drug will be launched in the coming weeks. In response, Leerink issued a price-target hike to $53 from $52, while an analyst at RBC noted the approval sets the tone for other important pipeline developments down the road. The news has MYL stock up 7.6% to trade at $41.44 in early trading.

Mylan stock is on pace for its best single-day performance since October. Since touching a high of $47.82 in late January, the equity has given back nearly 20%, carving out a channel of lower highs amid pressure from the 50-day moving average. However, today's move has the shares well above this key trendline. 

There's been plenty of skepticism levied toward the drug stock. MYL's 10-day put/call volume ratio of 1.47 at the International Securities Exchange (ISE), Chicago Board Options Exchange (CBOE), and NASDAQ OMX PHLX (PHLX) ranks in the elevated 91st annual percentile. The high percentile suggests the rate of put buying has been accelerated relative to call buying lately.

On the other side of the coin, Amgen, Inc. (NASDAQ:AMGN) stock is down 1% to trade at $183.53, as Fulphila will be a competitor to Neulasta, Amgen's own blockbuster infection drug. RBC promptly trimmed its price target to $183 from $184. 

On the charts, AMGN stock is currently riding a four-week winning streak since bouncing off the $165 level in early May. Despite the pullback today, AMGN is still trading above its year-to-date breakeven level, and has added 15% in the last 12 months. The stock also recently found itself on a list of the best S&P 500 stocks to own this summer. According to Schaeffer's Senior Quantitative Analyst Rocky White, AMGN in the past 10 years has averaged a return of 12.11% between the June-August period. 


A Schaeffer's exclusive

11 Stocks to Buy Before Leap Day

Access your FREE insider report before it's too late!


 
 

Partnercenter


NEW! Explore Schaeffer’s Partners' deals and get connected to top online brokerages with deals tailored exclusively for our readers.  Get answers to your questions regarding transfer fees, commission rates, programs and available discounts related to online trading services.

MORE | MARKETstories


The IRS Loopholes Retirees Need to Know
Click to continue to advertiser's site.
Morgan Stanley Waxes Optimistic on Keurig Dr Pepper Stock
KDP remains above its year-to-date breakeven point
Intuit Stock Joins Sell-Off After Credit Karma Buzz
INTU is on track for its worst day since late 2018
The IRS Loopholes Retirees Need to Know
Click to continue to advertiser's site.